Get the Stockscreener App
20.65
1.52%
0.31
After Hours:
20.65
Tourmaline Bio Inc stock is traded at $20.65, with a volume of 819.36K.
It is up +1.52% in the last 24 hours and down -13.96% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$20.34
Open:
$20.22
24h Volume:
819.36K
Relative Volume:
3.45
Market Cap:
$529.52M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
-133.48
EPS:
-0.1547
Net Cash Flow:
$-19.23M
1W Performance:
-5.32%
1M Performance:
-13.96%
6M Performance:
+36.66%
1Y Performance:
+8.68%
1-Day Range:
$20.20
$21.53
1-Week Range:
$19.14
$22.80
52-Week Range:
$12.12
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
20.65 | 529.52M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Fmr LLC Has $387,000 Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Graves Ophthalmopathy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts - EIN News
Wellington Management Group LLP Raises Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
The Manufacturers Life Insurance Company Buys 5,945 Shares of Orchid Island Capital, Inc. (NYSE:ORC) - Defense World
The Manufacturers Life Insurance Company Takes $226,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Holdings Lifted by Charles Schwab Investment Management Inc. - Defense World
Northrim BanCorp, Inc. (NASDAQ:NRIM) Shares Sold by BNP Paribas Financial Markets - Defense World
BNP Paribas Financial Markets Sells 1,132 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
BNP Paribas Financial Markets Sells 509 Shares of First Internet Bancorp (NASDAQ:INBK) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 74,430 Shares of The GEO Group, Inc. (NYSE:GEO) - Defense World
FY2025 EPS Estimates for Tourmaline Bio Increased by Analyst - Defense World
Analysts Issue Forecasts for Tourmaline Bio FY2025 Earnings - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Earns Buy Rating from HC Wainwright - Defense World
Tourmaline Bio's (TRML) Buy Rating Reiterated at HC Wainwright - MarketBeat
Tourmaline Bio expands trial and advisory board By Investing.com - Investing.com South Africa
Tourmaline Bio Updates on Clinical Progress and Outlook - TipRanks
Tourmaline Bio Unveils Clinical Progress and New Indication - TipRanks
Tourmaline Bio expands trial and advisory board - Investing.com
Tourmaline Announces the Over-Enrollment of its Phase 2 TRANQUILITY Trial - Marketscreener.com
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day - The Manila Times
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates - EIN News
Tourmaline Bio's TRANQUILITY Trial Surpasses Enrollment Target, Expands into Aortic Aneurysm Treatment - StockTitan
Tourmaline Bio to host investor day - MSN
Critical Analysis: Burford Capital (NYSE:BUR) & MARA (NASDAQ:MARA) - Defense World
338,437 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Bought by Point72 Asset Management L.P. - MarketBeat
BMO Capital Markets Begins Coverage on Tourmaline Bio (NASDAQ:TRML) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $61.25 Consensus Target Price from Analysts - MarketBeat
Likelihood of Approval and Phase Transition Success Rate ModelPacibekitug in Atherosclerosis - GlobalData
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Tourmaline Bio, Inc. (NASDAQ:TRML) is Acuta Capital Partners LLC's 3rd Largest Position - MarketBeat
Jennison Associates LLC Has $29.62 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 - InvisionMag
This Week in Ophthalmology: Week of November 11, 2024 - Ophthalmology Times
Blue Owl Capital Holdings LP Adjusts Stake in Tourmaline Bio Inc - GuruFocus.com
HC Wainwright Reduces Earnings Estimates for Tourmaline Bio - Defense World
HC Wainwright Lowers Earnings Estimates for Tourmaline Bio - MarketBeat
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 - The Manila Times
Midland Identifies Gold Potential on Its Caniapisc Au Project, James Bay - The Manila Times
Tourmaline Bio Sets Key Investor Day with Focus on Pacibekitug Development | TRML Stock News - StockTitan
Alternus Clean Energy Inc (NASDAQ:ALCE) Sees Significant Decrease in Short Interest - Defense World
Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) Short Interest Update - Defense World
Short Interest in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCYW) Decreases By 97.6% - Defense World
TruBridge (NASDAQ:TBRG) Price Target Raised to $14.00 - Defense World
Greenlane Renewables (OTCMKTS:GRNWF) Trading 21.2% Higher – Here’s What Happened - Defense World
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Tourmaline Bio ATM - SVB Leerink
Varonis Systems, Inc. (NASDAQ:VRNS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Tourmaline stock PT nudged by H.C. Wainwright, citing confidence in pacibekitug - Investing.com UK
Tourmaline Bio, Inc. Reports Third Quarter Financial Results - TipRanks
Tourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC Wainwright - MarketBeat
Tourmaline Bio Inc (TRML) Quarterly 10-Q Report - Quartzy
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tourmaline Bio Inc Stock (TRML) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
| MCDADE MARK | Director |
Jan 29 '24 |
Buy |
32.50 |
100,000 |
3,250,000 |
448,431 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):